Literature DB >> 24077286

Tumor resident mesenchymal stromal cells endow naïve stromal cells with tumor-promoting properties.

G Ren1, Y Liu2, X Zhao3, J Zhang4, B Zheng3, Z-R Yuan4, L Zhang4, X Qu5, J A Tischfield3, C Shao6, Y Shi1.   

Abstract

Bone marrow mesenchymal stem/stromal cells (BM-MSCs) can infiltrate into tumors and subsequently evolve into tumor resident MSCs in tumor microenvironment. In this study, using a mouse lymphoma model, we showed that the lymphoma resident MSCs (L-MSCs) are able to confer tumor-promoting property to the naïve cocultured BM-MSCs. Examination of cytokines and chemokines showed that post exposure to L-MSCs, BM-MSCs acquired an expression profile that is similar to that in L-MSCs. In vivo, BM-MSCs educated by L-MSCs (BM-L-MSCs) possess a greatly enhanced ability in promoting lymphoma growth. Consistent with an elevated CCL-2 expression in BM-L-MSCs, the tumor-promoting effect of BM-L-MSCs largely depends on CCR2-mediated macrophage recruitment to tumor sites. We further showed that the transmission of tumor-promoting effect is partially mediated by soluble factors. Our findings thus revealed a novel reinforcing mechanism in the maintenance of tumor microenvironment.

Entities:  

Mesh:

Year:  2013        PMID: 24077286     DOI: 10.1038/onc.2013.387

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

Review 1.  Tumor-resident adenosine-producing mesenchymal stem cells as a potential target for cancer treatment.

Authors:  Samaneh Arab; Akram Alizadeh; Samira Asgharzade
Journal:  Clin Exp Med       Date:  2021-01-23       Impact factor: 3.984

Review 2.  Tumor microenvironment promotes breast cancer chemoresistance.

Authors:  Umar Mehraj; Abid Hamid Dar; Nissar A Wani; Manzoor A Mir
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-09       Impact factor: 3.333

Review 3.  Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets.

Authors:  Yufang Shi; Liming Du; Liangyu Lin; Ying Wang
Journal:  Nat Rev Drug Discov       Date:  2016-11-04       Impact factor: 84.694

Review 4.  Mesenchymal stem cells: From regeneration to cancer.

Authors:  Peishan Li; Zheng Gong; Leonard D Shultz; Guangwen Ren
Journal:  Pharmacol Ther       Date:  2019-04-16       Impact factor: 12.310

Review 5.  Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation.

Authors:  Kisha Nandini Sivanathan; Stan Gronthos; Darling Rojas-Canales; Benjamin Thierry; P Toby Coates
Journal:  Stem Cell Rev Rep       Date:  2014-06       Impact factor: 5.739

6.  Gastric cancer-derived mesenchymal stem cells prompt gastric cancer progression through secretion of interleukin-8.

Authors:  Wei Li; Ying Zhou; Jin Yang; Xu Zhang; Huanhuan Zhang; Ting Zhang; Shaolin Zhao; Ping Zheng; Juan Huo; Huiyi Wu
Journal:  J Exp Clin Cancer Res       Date:  2015-05-20

7.  Type I interferons exert anti-tumor effect via reversing immunosuppression mediated by mesenchymal stromal cells.

Authors:  P Shou; Q Chen; J Jiang; C Xu; J Zhang; C Zheng; M Jiang; T Velletri; W Cao; Y Huang; Q Yang; X Han; L Zhang; L Wei; A B Rabson; Y E Chin; Y Wang; Y Shi
Journal:  Oncogene       Date:  2016-04-25       Impact factor: 9.867

8.  Pre-treatment of human umbilical cord-derived mesenchymal stem cells with interleukin-6 abolishes their growth-promoting effect on gastric cancer cells.

Authors:  Mei Wang; Jie Cai; Feng Huang; Mengchu Zhu; Qiang Zhang; Tingting Yang; Xu Zhang; Hui Qian; Wenrong Xu
Journal:  Int J Mol Med       Date:  2014-12-02       Impact factor: 4.101

9.  Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities.

Authors:  L Y Lin; L M Du; K Cao; Y Huang; P F Yu; L Y Zhang; F Y Li; Y Wang; Y F Shi
Journal:  Oncogene       Date:  2016-05-02       Impact factor: 9.867

10.  TNFα-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2+ neutrophils.

Authors:  P F Yu; Y Huang; Y Y Han; L Y Lin; W H Sun; A B Rabson; Y Wang; Y F Shi
Journal:  Oncogene       Date:  2016-07-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.